Purchase this article with an account.
S. Lee, J.–H. Jin, S.–D. Kim; The Effect of Intravitreal Triamcinolone Acetonide on Intraocular Pressure in Uveitis . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2441.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We performed a retrospective study to investigate intraocular pressure (IOP) changes after an intravitreal triamcinolone acetonide(IVTA) in uveitic patients and to compare them with those of other diseases.
We reviewed 12 patients(17 eyes) who were diagnosed as uveitis and treated by oral and dropping steroid, then injected triamcinolone acetonide in vitreous cavity in our hospital from March, 2003 to April, 2005. And we evaluated IOP changes of uveitic patients and compared them with those of diabetic retinopathy(DR, 21 eyes), branch retinal vein occlusion (BRVO, 11 eyes), and age–related macular degeneration(AMD, 5 eyes) who were also treated by IVTA.
The elevation of IOP(p=0.042) and maximum IOP(p=0.003) were significantly different in uveitic patients than other patients(DR, BRVO, AMD). The Mean age was not statistically different between IOP elevated group and not elevated group in uveitic patients, but IOP was significantly increased over 40 years old(p=0.04). IOP was more elevated in uveitic patients with short attack duration (p=0.03). The duration of developing IOP elevation was ranged between 1 to 10 weeks after IVTA in uveitic patients, and 2 eyes was received glaucoma surgery because of poorly controlled IOP.
IVTA in uveitc patients is useful method to reduce inflammation, but IOP elevation is more common in uveitc patients than other disease(DR, BRVO, AMD) and may be developed until 10 weeks, so enough follow up is recommended.
This PDF is available to Subscribers Only